Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. Agenus executives will host a conference call and webcast at 9:00 a.m. ET to discuss the results and to provide a corporate update. Key highlights include: Recent data shows that botensilimab (BOT), with or without balstilimab (BAL), is broadly effective in treating five advanced.

Agenus Reports Third Quarter 2023 Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023. About Agenus Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient.

Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat cancers, today announced first-time and updated data from its ongoing botensilimab/balstilimab (BOT/BAL) clinical programs in advanced colorectal cancer (CRC), neoadjuvant CRC, pancreatic cancer, non-small cell lung cancer (NSCLC), melanoma, and sarcoma. Members of the Agenus leadership team along with key opinion leaders will discuss these findings during a live webcast at.

Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company's phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with balstilimab (BAL, anti-PD-1) in patients with advanced sarcomas. The results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023. Relapsed/refractory sarcoma represents.

ESMO 2023: Agenus' Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensilimab (BOT) as monotherapy and in combination with balstilimab (BAL) or standard of care in patients with metastatic heavily pre-treated colorectal cancer. The phase 2.

Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reduction and focus on its most promising pipeline members will help to save ~$40M in costs through the end of 2023. An update on the botensilimab/balstilimab program is expected on October 22, which provides a near-term catalyst for the company.

Agenus: Getting The Tough Decisions Right With Catalysts Ahead

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023. Agenus will provide updates from the ongoing BOT/BAL clinical program, including in neoadjuvant colorectal cancer and pancre.

Agenus To Host BOT/BAL Program Update at ESMO 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted, as of September 1, 2023 (“Grant Date”), inducement awards to Robin Taylor, Ph.D. in connection with his appointment as Chief Commercial Officer. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with.

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals

Nano-X Imaging

Growth stocks have slumped in August. This broad sell-off has created some compelling buying opportunities.

3 Magnificent Growth Stocks to Buy on the Dip

LEXINGTON, Mass.LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference – Fireside chat presentation will be held in-person on Thursday, September 7th, 2023, at 11:00 a.m. ET in Boston, MA. A live webcast and replay will be accessible on the comp.

Agenus to Participate in September Investor Conferences

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program botensilimab/balstilimab (BOT/BAL). Under this new plan, Agenus will temporarily postpone all preclinical and clinical programs not related to BOT/BAL. The plan will result in a workforce reduction of approximately 25% and deliver.

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

LEXINGTON, Mass.--(BUSINESS WIRE)--SaponiQx, the adjuvant subsidiary of Agenus Inc. (NASDAQ: AGEN), specializing in saponin-based adjuvant discovery and manufacturing, has achieved a milestone in scaling the production of its STIMULON cultured plant cell (cpc) QS-21 adjuvant, designed to amplify the efficiency and endurance of vaccines. This cultured plant cell adjuvant is building upon SaponiQx's expertise with its proprietary adjuvant STIMULON QS-21, a critical component of effective vaccines.

SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant

While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. Key accomplishments and highlights include: Botensilimab Update: Botensilimab/balstilimab combination data presented at ESMO-GI demonstrated median overall survival (mOS) of 20.9 months and a 23% overall response rate (ORR), both surpassing data reported for standard of care in 3L+ Non-MSI-H col.

Agenus Reports Second Quarter 2023 Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain. Presentation Details: Abstract Title: Efficacy and safety of boten.

Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023. In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences: BTIG Virtual Biotechnology Conference 2023 – Fireside chat presentation will be held virtually on Monday, August 7th, 2023 at 3:00 PM ET. A re.

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chie.

Agenus Expands Executive Leadership Team

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking session at the 2023 ESMO World Congress on Gastrointestinal Cancer (ESMO GI). The new data show substantial survival benefits and long-lasting responses for patients with non-MSI-H (microsatellite stable or non-microsatellite instability-high) metastatic colorectal cancer previously resistant to c.

ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Aclaris Therapeutics

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.

2 Low-Priced Stocks That Could Make You Richer

Agenus Inc (NASDAQ:AGEN) and its optimized approach on a validated mechanism (CTLA-4) offer a rare investible opportunity in immuno-oncology (IO), wrote Baird Equity Research analysts in a note published on Monday. They initiated coverage of the clinical-stage biopharmaceutical company focused on developing and commercializing IO therapies with an ‘Outperform' rating and $8 per share price target.

Agenus is “turning cold tumors hot and making CTLA-4 cool again”

Agenus Inc. has existed for a long three decades, doing nothing much really. They have been producing very strong data from botensilimab lately. Agenus Inc. prospects could now change for the better.

Agenus: This Time May Be Different

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors.

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit http://www.virtualshareholdermeeting.com/AGEN20.

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Jefferies Healthcare Conference on June 8th at the Marriot Marquis in New York. The fireside chat will take place at 1pm ET on June 8th. A live webcast of the fireside can be accessed on the company's w.

News for Agenus Stock (AGEN)